Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist).

Br J Cancer · 2017 · PMC5318972 · PMID 28118323

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Chemotherapy side effects symptoms were more common in the chemotherapy arm; however, the difference did not reach statistical significance.

also in 111,027 other papers

marginally significantno p-value reported

There was also a marginally significant benefit in OS in patients who had received paclitaxel plus bevacizumab ( Poveda et al , 2015 ).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.